KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.2368
-0.0091 (-3.70%)
At close: Mar 20, 2026, 4:00 PM EDT
0.2370
+0.0002 (0.08%)
After-hours: Mar 20, 2026, 7:43 PM EDT
KALA BIO Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
1.94M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 3.89M | -7.35M | -65.37% |
| Dec 31, 2021 | 11.24M | 4.88M | 76.67% |
| Dec 31, 2020 | 6.36M | 288.00K | 4.74% |
| Dec 31, 2019 | 6.07M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 45.00K | -410.00K | -90.11% |
| Dec 31, 2014 | 455.00K | 405.00K | 810.00% |
| Dec 31, 2013 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 11.79M |
| Ensysce Biosciences | 4.49M |
| 60 Degrees Pharmaceuticals | 1.36M |
| Scinai Immunotherapeutics | 1.15M |
| Onconetix | 815.37K |
| HCW Biologics | 422.03K |
| BioRestorative Therapies | 383.40K |
KALA News
- 4 days ago - Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate - GlobeNewsWire
- 4 days ago - Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - Newsfile Corp
- 11 days ago - Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents - Newsfile Corp
- 11 days ago - Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates - GlobeNewsWire
- 13 days ago - Stock Trend Capital Provides Younet AI Investment Update - Newsfile Corp
- 18 days ago - KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency” - GlobeNewsWire
- 2 months ago - KALA BIO Settles Approximately $10.6 million of Debt - GlobeNewsWire
- 3 months ago - KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire